ACTUATE THERAPEUTICS EXPANDED ACCESS POLICY Actuate Therapeutics (“Actuate”) is dedicated to developing transformative clinical outcomes for patients suffering from advanced, hard-to-treat cancers, many of which are fatal with limited or no treatment options. We are committed to developing innovative therapies as quickly as our clinical programs, data review, and regulatory requirements allow. Through the inhibition […]
Expanded Access Policy Read More »
November 26, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers announced today that the Company will be added to the Russell 2000® Index as part
Actuate Therapeutics to be Added to Russell 2000® Index Read More »
October 29, 2024 18:39 ET Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development Read More »
April 08, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The abstracts are
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting Read More »
INVESTOR OVERVIEW Corporate profile Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential
CORPORATE GOVERNANCE Documents & Charters Audit Committee Charter Compensation Committee Charter Nominating & Corporate Governance Committee Charter Code of Business Conduct & Ethics Corporate Governance Guidelines Other Links View Our Management View Our Board of Directors Committee Composition Audit Compensation Nominating and Corporate Governance Committee Daniel Zabrowski Chair Member Roger Sawhney Member Member Amy Ronneberg
Corporate Governance Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today four presentations from scientific collaborators at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 2 – 6, 2023, in Chicago, Illinois. The abstracts are currently available on the ASCO meeting website. The
ACTUATE THERAPEUTICS ANNOUNCESPOSTER PRESENTATIONS AT THE 2023 ASCO ANNUAL MEETING Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida. The abstracts are currently available on the AACR meeting website. The posters will
ACTUATE THERAPEUTICS ANNOUNCES POSTER PRESENTATIONS AT THE 2023 AACR ANNUAL MEETING Read More »
CHICAGO, IL and FORT WORTH, TX, March 23, 2023 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been elected as President-Elect of the American Association of Cancer Research for
